In a bid to reduce healthcare costs, Oregon wants to create a closed formulary limiting the number of drugs in each class and potentially excluding drugs approved under the FDA’s…
Final data from the phase 2/3 study of Pfizer’s novel oral “at home” COVID-19 treatment, Paxlovid, was so strong, the candidate could be well-positioned to knock molnupiravir — which is…
The Senate Finance Committee has released amended Build Back Better Act text, which would exempt generics and biosimilars at risk of supply chain shortages from rebates drugmakers would have to…
Gilead and Bristol-Myers Squibb (BMS) are touting positive data from studies of their bespoke CAR-T cell treatments, each company hailing the results as a new treatment era for patients with…
A federal judge has issued an injunction temporarily halting a California law outlawing “pay-for-delay” agreements between branded drug manufacturers and makers of generics. Source: Drug Industry Daily
The FDA’s Center for Biologics Evaluation and Research (CBER) has issued a temporary policy guidance addressing the COVID-19-related shortage of Roche’s blockbuster immunosuppressive tocilizumab, which the FDA requires to be…
Pfizer announced that it will buy Park City, Utah-based Arena Pharmaceuticals for $6.7 billion, pumping up its portfolio of therapies for immuno-inflammatory diseases. Source: Drug Industry Daily
Moderna says its messenger RNA flu vaccine candidate, mRNA-1010, successfully boosted titers against all four influenza strains it’s being tested against during an ongoing phase 1 study, even at lowest…
In a final guidance released Friday, the FDA adopted International Council for Harmonization (ICH) guidelines for three solvents used in drug manufacturing processes, based on the most up-to-date data on…
Johnson & Johnson (J&J) has appointed new members to its executive committee ahead of splitting its pharmaceuticals and over-the-counter consumer products businesses within the next two years. Source: Drug Industry…